Illinois · Nonprofit
MUSCULOSKELETAL TUMOR SOCIETY
MUSCULOSKELETAL TUMOR SOCIETY (Illinois) receives grants from 5 organizations whose IRS filings report $467,198 to it, the largest being SARCOMA STRONG INC ($322,000). 4 of them have funded it in more than one year.
- Revenue FY2024
- $1.0M
- Funders on record
- 5
- Grants received
- $467k
- Net assets
- $1.9M
What Musculoskeletal Tumor Society does
Mission
The mission of the Musculoskeletal Tumor Society is to advance the science of orthopaedic oncology and to promote high standards of patient care. It does this through excellence in education and research and through advocacy on behalf of patients and orthopaedic oncologists.
As stated on its FY2024 Form 990.
Programs
Annual meeting- a forum where orthopaedic surgeons who specialize in bone tumor cancers can be educated on the latest research and treatments.
$440,204 spent$491,963 earned by the program64% of program spendingSpecialty day - a one day program for orthopaedic surgeons to shareorthopaedic oncology information during the american academy oforthopaedic surgeons meetings.
$26,324 spent$31,063 earned by the program4% of program spendingGrants and awards - the board allocates research funding to advanceresearch in the specialty of orthopaedics. The board is responsiblefor establishing criteria for the distribution of funds raised,conducting an independent peer review process, preparing promotionalinformation and distributing applications for research grants andawards, and making decisions regarding the awarding of funds for research consistent with program goals and objectives.
$198,137 spentof which $198,137 as grants29% of program spendingOther programs
$21,026 spent$178,588 earned by the program3% of program spending
The 4 programs described on its FY2024 Form 990, listed largest first by expense. Program spending in total: $685,691.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2018 to 2019, from $1.3M to $1.5M (+17%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
34% of MUSCULOSKELETAL TUMOR SOCIETY’s revenue is contributions — about as donation-reliant as the typical peer (51% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 2 of the last 8 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Chief executive
Kerri Mink
Executive director
As listed on its FY2024 Form 990.
Who funds it, year by year
2017 → 2023: the base narrowed from 2 funders to 1 funder, grant income fell $60k → $0.
From the IRS filings of MUSCULOSKELETAL TUMOR SOCIETY’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
MUSCULOSKELETAL TUMOR SOCIETY leans on a few funders — its largest provides 69% of grant income and the top three 97%; half comes from just 1 funder.
the vertical line marks half of all grant income — 1 funder to its left
100% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund MUSCULOSKELETAL TUMOR SOCIETY.
Largest funder’s share by year: 2017 83% · 2018 100% · 2020 92% · 2022 100% — growing more concentrated.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Where its funders are
MUSCULOSKELETAL TUMOR SOCIETY draws 91% of its grant income from funders outside Illinois, across 4 states in all.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
MUSCULOSKELETAL TUMOR SOCIETY's revenue grew 60% between 2017 and 2024.
this organization peer median middle 50% of peers· 8,126 health nonprofits $1M–$10M, FY2024
Organizations like MUSCULOSKELETAL TUMOR SOCIETY
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In Illinois
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
61% of spending goes to programs.
Governance
Public support
82%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 1 state
Screen this organization
A dated, signed PDF of the compliance screen for MUSCULOSKELETAL TUMOR SOCIETY: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds MUSCULOSKELETAL TUMOR SOCIETY?
- MUSCULOSKELETAL TUMOR SOCIETY (Illinois) receives grants from 5 organizations whose IRS filings report $467,198 to it, the largest being SARCOMA STRONG INC ($322,000). 4 of them have funded it in more than one year.
- How many funders does MUSCULOSKELETAL TUMOR SOCIETY have?
- IRS filings report 5 organizations giving $467,198 in grants to MUSCULOSKELETAL TUMOR SOCIETY, 4 of which have funded it in more than one year.
- Who is the largest funder of MUSCULOSKELETAL TUMOR SOCIETY?
- SARCOMA STRONG INC is the largest funder on record, with $322,000 in grants. The full list of funders is on this page.
- How can an organization like MUSCULOSKELETAL TUMOR SOCIETY find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in Illinois. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 5 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 22, 2026. What this page cannot tell you · view filing